Literature DB >> 7590102

Molecular pharmacology of V1a vasopressin receptors.

J Howl1, M Wheatley.   

Abstract

1. Vasopressin, a mammalian neurohypophysial peptide hormone, has diverse physiological actions. 2. Pharmacological studies, using a range of mammalian tissues, have identified three subtypes of vasopressin receptor. 3. The V1a subtype of vasopressin receptor is widely distributed and mediates many central and peripheral actions of vasopressin. 4. The development of subtype-selective vasopressin analogues has provided valuable tools for pharmacological and physical studies of the V1a receptor protein. 5. Pharmacological differences indicate species heterogeneity in the characteristics of V1a receptors and in the expression of hepatic V1a receptors. 6. The cloning of neurohypophysial hormone receptor proteins allows structural and functional comparison of the V1a vasopressin receptors with other G-protein-coupled receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7590102     DOI: 10.1016/0306-3623(95)00016-t

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  8 in total

1.  Molecular recognition of peptide and non-peptide ligands by the extracellular domains of neurohypophysial hormone receptors.

Authors:  J Howl; M Wheatley
Journal:  Biochem J       Date:  1996-07-15       Impact factor: 3.857

Review 2.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

3.  Identification of the glycosylation sites utilized on the V1a vasopressin receptor and assessment of their role in receptor signalling and expression.

Authors:  S R Hawtin; A R Davies; G Matthews; M Wheatley
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

4.  Controlled and cardiac-restricted overexpression of the arginine vasopressin V1A receptor causes reversible left ventricular dysfunction through Gαq-mediated cell signaling.

Authors:  Xue Li; Tung O Chan; Valerie Myers; Ibrul Chowdhury; Xue-Qian Zhang; Jianliang Song; Jin Zhang; Jocelyn Andrel; Hajime Funakoshi; Jeffrey Robbins; Walter J Koch; Terry Hyslop; Joseph Y Cheung; Arthur M Feldman
Journal:  Circulation       Date:  2011-07-11       Impact factor: 29.690

5.  The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*.

Authors:  Marc O Maybauer; Dirk M Maybauer; Perenlei Enkhbaatar; Régent Laporte; Halina Wiśniewska; Lillian D Traber; ChiiDean Lin; Juanjuan Fan; Hal K Hawkins; Robert A Cox; Kazimierz Wiśniewski; Claudio D Schteingart; Donald W Landry; Pierre J-M Rivière; Daniel L Traber
Journal:  Crit Care Med       Date:  2014-07       Impact factor: 7.598

Review 6.  Cardiogenic shock in ACS. Part 2: Role of mechanical circulatory support.

Authors:  Stephen Westaby; Kyriakos Anastasiadis; George M Wieselthaler
Journal:  Nat Rev Cardiol       Date:  2012-01-10       Impact factor: 32.419

7.  Novel strategies for the design of receptor-selective vasopressin analogues: Aib-substitution and retro-inverso transformation.

Authors:  J Howl; Z Prochazka; M Wheatley; J Slaninová
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

Review 8.  Role of various neurotransmitters in mediating the long-term endocrine consequences of prenatal alcohol exposure.

Authors:  Soon Lee; Irene Choi; Sang Kang; Catherine Rivier
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.